Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026
HealthTreeDescription
Jeffrey Zonder, MD, of Karmanos Cancer Institute discusses first results from the IBEX study of iberdomide plus subcutaneous daratumumab as maintenance after stem cell transplant at IMS 2026 in Glasgow. Some patients still have detectable myeloma even after quadruplet induction and transplant. He reviews the side effects seen, including infections, rashes and low white blood cell counts, with no new safety signals. Early results suggest the combination can deepen responses and help some patients become MRD negative.
Timestamps:
0:00 Introduction
0:12 The IBEX study
0:40 Who was enrolled and how it was dosed
1:28 Dose change and new primary endpoint
1:52 Why sustained MRD negativity matters
2:51 Safety: infections, rashes, second cancers
4:03 Low blood counts
4:54 Efficacy: deeper responses and MRD
6:34 Where the study stands